Guidepoint Qsight Data revealed its “Impact Players 2026” — a list of the top medical aesthetics brands across all categories, recognizing industry impact through verified market data.
Released on March 24, 2026, the second annual report identified top performers based on Guidepoint Qsight’s proprietary transaction, social intelligence, and practitioner survey data.
Related: Plastic Surgery Hotspots Across U.S. Revealed
The metrics measured were sales growth, category growth, practice profitability, social media share of voice, market share and growth and patient retention.
The report ranked the top five brands across 4 categories within medical aesthetics, breast implants, professional grade skincare, energy-based device skin rejuvenation and resurfacing, and mechanical microneedling. Winners are selected for the impact they have on the market, not just their presence within it
“The medical aesthetics sector remains highly dynamic as it continues to evolve across categories and patient demand. The brands highlighted here have not only impacted the market, but have also helped define it. We’re pleased to recognize those that have meaningfully shaped their categories over the past year,” noted Erik Haines, Managing Director of Guidepoint Qsight.
2026 Impact Players:
- Motiva by Establishment Labs: for Social Media Share of Voice Leader — Breast Implants
- (plated) Skin Science by Rion Aesthetics: for Highest Sales Growth – Professional Grade Skincare
- BBL HERO / BBL HEROic by Sciton: for Category Growth Leader — Energy-Based Device Skin Rejuvenation & Resurfacing
- SkinPen by Revance: for Market Share & Growth Leader — Mechanical Microneedling
- ZO Skin Health: for Highest Patient Retention — Professional Grade Skincare
“These recognitions, based on our proprietary data and deep sector analysis, reflect the breadth and depth of the medical aesthetics industry into 2026 and beyond,” continued Haines. “Standout performances across categories and brands underscore that meaningful opportunities remain for those responding to evolving patient demand.”
Please find the full report here.
